

22-11-2019

09:30 - 11:30 Opening session Hall 406

11:45 - 12:30 Immunotherapy in GU cancers: Focus on kidney and bladder cancers Summit 1
Moderation: C.N. Sternberg, New York, US

11:45 - 11:55 **Kidney**
Y.L. Su, Kaohsiung, TW

11:55 - 12:05 **Bladder**
R. Kanesvaran, Singapore, SG

12:05 - 12:30 **Discussion**

11:45 - 12:30 Surgical Management of Ovarian Cancer Hall 407
Moderation: A. Maheshwari, Mumbai, IN

11:45 - 12:00 **Surgical Management of Ovarian Cancer**

12:00 - 12:30 **Discussion**

11:45 - 12:30 Locally advanced nasopharyngeal carcinoma (LA NPC): Asian and Summit 2
European perspectives

11:45 - 12:00 **Locally advanced nasopharyngeal carcinoma (LA NPC): Asian and European perspectives**
A. Chan¹, P. Blanchard²; ¹Shatin, HK, ²Villejuif, FR

12:00 - 12:30 **Discussion**

11:45 - 12:30 Optimal sequence and treatment choice in osimertinib failure Hall 404
Moderation: M. Ahn, Seoul, KR

11:45 - 12:00 **Optimal sequence and treatment choice in osimertinib failure**
T.S.K. Mok, Shatin, HK

12:00 - 12:30 **Discussion**

14:30 - 16:00 Integrating new treatment paradigms in breast cancer care in 2019 Hall 405

14:30 - 14:55 **HER2-positive breast cancer: Escalation and de-escalation strategies in the neo/adjuvant setting, who and when**

14:55 - 15:20 **Triple negative advanced breast cancer: Immunotherapy incorporation, who and when**

G. Curigliano, Milan, IT

15:20 - 15:45 **HR-positive advanced breast cancer: CDK4 inhibitors, who and when**

S. Goel, Boston, US

15:45 - 16:00 **Discussion**

14:30 - 16:00 Precision medicine in advanced gastrointestinal cancer Hall 407

Moderation: T. Yoshino¹, C. Cremolini²; ¹Kashiwa, Chiba/JP, ²Pisa, IT

14:30 - 14:50 **Clinical applications of circulating tumour DNA in advanced setting**

C. Cremolini, Pisa, IT

14:50 - 15:10 **Targeted treatment in gastroesophageal cancer: The present and the future**

S. Lorenzen, Munich, DE

15:10 - 15:30 **Precision medicine in metastatic colorectal cancer**

T.W. Kim, Seoul, KR

15:30 - 16:00 **Discussion**

14:30 - 16:00 Contemporary issues in cervical cancer management Summit 2

14:30 - 14:35 **Presentation of case/condition**

T. Sadaf, Lahore, PK

14:35 - 14:50 **Pre-treatment evaluation and revised FIGO staging**

S. Gupta, Mumbai, IN

14:50 - 15:05 **Surgical management: When and how?**

K. Fujiwara, Saitama, JP

15:05 - 15:20 **Is there a role of neoadjuvant chemotherapy?**

15:20 - 15:35 **Primary and secondary prevention**

N. Bhatla, Delhi, IN

15:35 - 16:00 **Discussion**

14:30 - 16:00 Improving cancer care in Asia Room 325

Moderation: G.S. Bhattacharyya¹, S. Aung²; ¹Kolkata, West Bengal/IN, ²Yangon, Yangon/MM

14:30 - 14:50 **Challenges in implementing National Cancer Control Plans in LMCs**

A. Ilbawi, Geneva, CH

14:50 - 15:10 **Population-based cancer registries in Asia**

G.S. Bhattacharyya, Kolkata, West Bengal/IN

15:10 - 15:30 **Using cancer registries for drug development: the Japanese experience**

15:30 - 15:50 **How to measure and improve quality of cancer care in Asia**

S. Aung, Yangon, Yangon/MM

15:50 - 16:00 **Discussion**

16:30 - 18:00 Tumour agnostic drug development **Room 326**
Moderation: C. Dittrich, Vienna, AT

16:30 - 16:50 **Challenges of different genomic platforms used to select patients**
R. Bernards, Amsterdam, NL

16:50 - 17:10 **Basket trial design in tumour agnostic drug development**
C. Dittrich, Vienna, AT

17:10 - 17:30 **Targeted therapy with TRK inhibitors in tumours with NTRK fusion**
D.S.W. Tan, Singapore, SG

17:30 - 17:50 **Basket trials in rare cancer in Japan (and an overview of Asia)**
K. Yonemori, Tokyo, JP

17:50 - 18:00 **Discussion**

16:30 - 18:00 Precision immunotherapy **Hall 405**
Moderation: H.C. Toh¹, E. Romano²; ¹Singapore, SG, ²Paris, CEDEX 5/FR

16:30 - 16:45 **Basic concepts arguing for the use of neoadjuvant immunotherapy**
M. Teng, Brisbane, AU

16:45 - 17:00 **Precision medicine in cellular therapies: How can we identify patients who would benefit most**
A. Gros, Barcelona, ES

17:00 - 17:15 **New biomarkers for checkpoint inhibitor therapy**
J. Desai, Melbourne, VIC/AU

17:15 - 17:30 **Basic concepts in overcoming adaptive immune resistance**
A. Mantovani, Milan, IT

17:30 - 18:00 **Discussion**

16:30 - 18:00 **The multi-modality approach to sarcomas: Balancing cure and quality of life** **Summit 2**
Moderation: A. Constantinidou, Nicosia, CY

16:30 - 16:32 **Introduction**
A. Constantinidou, Nicosia, CY

16:32 - 16:47 **Localized disease: Retroperitoneal**
A. Hong, Sydney, AU

16:47 - 17:02 **Locally advanced disease**
M. Endo, Fukuoka, JP

17:02 - 17:17 **Oligo metastatic (focusing on lung metastases)**
A. Constantinidou, Nicosia, CY

17:17 - 17:32 **Multi-focal metastatic**
F. Gracieux Jr., Manila, PH

17:32 - 17:57 **Panel discussion**

17:57 - 18:00 **Conclusions**

23-11-2019

08:00 - 08:45 To use or not to use: Genomics assays in guiding adjuvant treatment of HR positive breast cancer **Hall 407**
Moderation: S.C. Lee¹, G. Curigliano²; ¹Singapore, SG, ²Milan, IT

08:00 - 08:15 **To use or not to use: Genomics assays in guiding adjuvant treatment of HR positive breast cancer**
F. Cardoso, Lisbon, PT

08:15 - 08:45 **Discussion**

08:00 - 08:45 Immunotherapy in gastroesophageal cancers: Present and future **Hall 404**
Moderation: K. Muro, Nagoya, Aichi/JP

08:00 - 08:15 **Immunotherapy in gastroesophageal cancers: Present and future**
F. Lordick, Leipzig, DE

08:15 - 08:45 **Discussion**

08:00 - 08:45 Management of irAEs in patients from Asia **Summit 1**
Moderation: E. Romano, Paris, CEDEX 5/FR

08:00 - 08:25 **Management of irAEs in patients from Asia**
H. Kao, Taipei, TW

08:25 - 08:45 **Discussion**

08:00 - 08:45 How to manage toxicity of immunotherapy **Summit 2**
Moderation: M.F. Harunal Rashid, Singapore, SG

08:00 - 08:15 **How to manage toxicity of immunotherapy**
J. Haanen, Amsterdam, NL

08:15 - 08:45 **Discussion**

09:00 - 10:30 Precision medicine for GU cancer **Hall 404**
 Moderation: A.A. Azad¹, C.N. Sternberg²; ¹Clayton, British Columbia/AU, ²New York, US

09:00 - 09:25 **Precision Medicine in prostate cancer**
C. Sternberg, New York, US

09:25 - 09:50 **Molecular dissection on bladder cancer**
B. Tran, Melbourne, AU

09:50 - 10:15 **mRCC treatment in 2019: current paradigms and future directions**
M. Schmidinger, Vienna, AT

10:15 - 10:30 **Discussion**

09:00 - 10:30 The interface between histopathology, genomics and therapy **Room 326**
 Moderation: T.W. Chen¹, S. Stacchiotti²; ¹New Taipei City, TW, ²Milan, IT

09:00 - 09:15 **New Insights in pathology: The WHO classification**
A. Yoshida, Tyu-Ouku, JP

09:15 - 09:30 **Translational Research: Genomics**
T.W. Chen, New Taipei City, TW

09:30 - 09:45 **Surgical perspective on improved pathological classification of tumours**
M. Teo, Singapore, SG

09:45 - 10:00 **Medical oncology on improved pathological classification of tumours**
S. Stacchiotti, Milan, IT

10:00 - 10:30 **Discussion**

14:30 - 16:00	Management of young patients with residual disease after preoperative chemotherapy Moderation: O. Pagani, Bellinzona, CH	Hall 407
14:30 - 14:35	Presentation of case/condition <u>O. Pagani</u> , Bellinzona, CH	
14:35 - 14:50	Addressing residual disease in 2019 <u>S. Kim</u> , Seoul, KR	
14:50 - 15:05	Surgical challenges	
15:05 - 15:20	Loco-regional radiotherapy: Shall we target the initial or residual disease burden? <u>B. Chua</u> , Randwick, VIC/AU	
15:20 - 15:35	Treatment side effects; balancing effectiveness and long-term sequelae <u>A. Eniu</u> , Cluj-Napoca, RO	
15:35 - 16:00	Discussion	
14:30 - 16:00	Precision medicine in ovarian and endometrial cancer Moderation: M.R. Mirza ¹ , S. Pignata ² , D.S. Tan ³ ; ¹ Copenhagen, DK, ² Napoli, IT, ³ Singapore, SG	Summit 1
14:30 - 14:55	Therapeutic genetic testing <u>D.S. Tan</u> , Singapore, SG	
14:55 - 15:20	Integrating PARP inhibition <u>M.R. Mirza</u> , Copenhagen, DK	
15:20 - 15:45	Novel treatments - immunotherapy and beyond <u>S. Pignata</u> , Napoli, IT	
15:45 - 16:00	Discussion	

14:30 - 16:00 **New advances in frequent lymphomas** **Room 326**
 Moderation: M.H. Dreyling¹, S.T. Lim²; ¹Munich, DE, ²Singapore, SG

14:30 - 14:55 **Advances in the management of the NK-T cell lymphomas**
W.S. Kim, Seoul, KR

14:55 - 15:20 **What is new in the classification and management of DLBCL in 2019**
K. Izutsu, Tokyo, JP

15:20 - 15:45 **Novel management of follicular lymphoma based on biological insights and novel concepts**
M. Ladetto, Alessandria, IT

15:45 - 16:00 **Discussion**

14:30 - 16:00 **Immuno-oncology** **Hall 404**
 Moderation: A.T.C. Chan¹, L.F. Licitra²; ¹Shatin, HK, ²Milan, IT

14:30 - 14:55 **Immune checkpoint inhibition and biomarkers in HNSCC**
L. Licitra, Milan, IT

14:55 - 15:20 **Immune checkpoint inhibition and biomarkers in NPC**
B. Ma, Shatin, HK

15:20 - 15:45 **Beyond immune checkpoint inhibition**
S. Oosting, Groningen, NL

15:45 - 16:00 **Discussion**

14:30 - 16:00 Overcoming challenges in cancer research in Asia **Room 325**
 Moderation: F. Cardoso¹, P. Chow²; ¹Lisbon, PT, ²Singapore, SG

14:30 - 14:50 **Harmonization of regulatory requirements for clinical and translational research and treatment approvals**
C.J. Cairo, Metro Manila, PH

14:50 - 15:10 **Hurdles imposed by regulatory agencies: are they all needed?**
B. Gyawali, Boston, Aichi/US

15:10 - 15:30 **Defining adequate endpoints and meaningful clinical benefit**
F. Cardoso, Lisbon, PT

15:30 - 15:50 **How to conduct multinational academic trials in Asia**

15:50 - 16:00 **Discussion**

14:30 - 16:00 Immuno oncology in specific populations **Hall 405**
 Moderation: F. Barlesi, Marseille, CEDEX 20/FR

14:30 - 14:55 **Clinical considerations (PS2, Elderly and Brain mets, autoimmuno diseases)**
C. Baldini, Villejuif, CEDEX/FR

14:55 - 15:20 **Biological considerations (Hepatitis, HIV, TB)**

15:20 - 15:45 **Re-challenging in patients with prior irAEs**

15:45 - 16:00 **Discussion**

16:30 - 18:00 Infectious disease and Cancer therapy: tips for daily practice of oncology Hall 405

16:30 - 16:55 **Vaccinating your cancer patients - When to vaccinate your solid tumour patient and health care professionals**

S. Cinieri, Brindisi, IT

16:55 - 17:20 **Why to screen for hepatitis if immuno/chemotherapy is contemplated**

W. Yeo, Shatin, HK

17:20 - 17:45 **How to prevent reactivation of tuberculosis**

17:45 - 18:00 **Discussion**

24-11-2019

09:15 - 10:45 Perspective of liquid biomarkers for cancer care Summit 1

09:15 - 09:35 **Methodology of liquid biopsy**

I. Tan, Singapore, SG

09:35 - 09:55 **Liquid biomarkers for NSCLC**

Y. Goto, Tokyo, JP

09:55 - 10:15 **Liquid biomarkers for advanced GI cancer**

10:15 - 10:35 **Liquid biomarkers for immunotherapy**

F.C. Bidard, Paris, CEDEX 5/FR

10:35 - 10:45 **Discussion**

09:15 - 10:45 Adjuvant treatment in gastrointestinal cancer Hall 405

Moderation: A. Sobrero, Genova, IT

09:15 - 09:30 **Minimal residual disease (overview lecture)**

09:30 - 09:45 **Colorectal cancer**

A. Sobrero, Genova, IT

09:45 - 10:00 **Pancreatic cancer**

M. Ducreux, Villejuif, CEDEX/FR

10:00 - 10:15 **Gastric cancer**

Y. Kodera, Nagoya, Aichi/JP

10:15 - 10:45 **Discussion**

09:15 - 10:45 Advanced prostate cancer (hormone-naïve case) Hall 407
Moderation: R. Kanesvaran, Singapore, SG

09:15 - 09:20 **Presentation of case/condition**
R. Kanesvaran, Singapore, SG

09:20 - 09:40 **Medical oncology perspective**
S. Gillessen, Manchester, GB

09:40 - 09:55 **Surgery perspective**
L.S. Lee, Singapore, SG

09:55 - 10:15 **Radiation oncology perspective**
D. Poon, Shatin, HK

10:15 - 10:45 **Discussion**

09:15 - 10:45 Challenges in the management of clinical stage N2 disease Hall 404
Moderation: S. Popat, London, GB

09:15 - 09:20 **Presentation of case/condition**
S. Popat, London, GB

09:20 - 09:40 **Medical oncologist's perspective**
E. Felip, Barcelona, ES

09:40 - 10:00 **Radiation oncologist's perspective**
Y.C. Ahn, Seoul, KR

10:00 - 10:20 **Thoracic surgeon's perspective**
T. Mitsudomi, Osaka, JP

10:20 - 10:45 **Discussion**

12:45 - 14:15 **Current controversies in the management of primary and secondary liver cancer** **Hall 405**
 Moderation: S. Lorenzen¹, E. Oki²; ¹Munich, DE, ²Fukuoka, JP

12:45 - 12:50 **Presentation of case/condition**
E. Oki, Fukuoka, JP

12:50 - 13:10 **The viewpoint of a Medical oncologist**
T. Yoshino, Kashiwa, Chiba/JP

13:10 - 13:30 **The viewpoint of a Surgical oncologist**
J. Xu, Shanghai, Changning/CN

13:30 - 13:50 **The viewpoint of an Interventional radiologist**
T. de Baere, Villejuif, FR

13:50 - 14:15 **Discussion**

12:45 - 14:15 **Melanoma treatment today and tomorrow** **Hall 404**
 Moderation: C. Robert, Villejuif, FR

12:45 - 13:05 **Adjuvant vs neoadjuvant therapy**
R. Dummer, Zurich, CH

13:05 - 13:25 **New combinations in metastatic disease**
C. Robert, Villejuif, FR

13:25 - 13:45 **Update on mucosal melanoma**
L. Si, Beijing, CN

13:45 - 14:05 **Management of acral melanoma**
A. Otsuka, Kyoto, JP

14:05 - 14:15 **Discussion**

12:45 - 14:15	Early integration of palliative care	Summit 1
12:45 - 13:15	Current status and future directions of ESMO Designated Centers: A global perspective <u>S. Kaasa</u> ¹ , <u>Y. Matsumoto</u> ² ; ¹ Oslo, NO, ² Kashiwa, Chiba/JP	
13:15 - 13:45	Focus on the top 4 symptoms and guidelines <u>M. Mori</u> ¹ , <u>N. Cherny</u> ² ; ¹ Hamamatsu, JP, ² Jerusalem, IL	
13:45 - 14:00	ESMO supportive and palliative care Guidelines <u>M. Aapro</u> , Genolier, CH	
14:00 - 14:15	Discussion	
14:30 - 16:00	New advances in the management of challenging lymphomas Moderation: <u>W.S. Kim</u> ¹ , <u>M. Ladetto</u> ² , <u>Y. Kwong</u> ³ ; ¹ Seoul, KR, ² Alessandria, IT, ³ Hong Kong, HK	Summit 1
14:30 - 14:50	Management of Hodgkin's lymphoma after failure of autologous stem cell transplant	
14:50 - 15:10	What is the best regiment and sequencing for treatment of mantle cell lymphoma <u>M. Dreyling</u> , Munich, DE	
15:10 - 15:30	New genetic insights to peripheral t cell lymphoma with a focus on angioimmunoblastic T cell lymphoma <u>M. Sakata-Yanagimoto</u> , Tsukuba, JP	
15:30 - 15:50	Current and novel treatment options for peripheral t cell Lymphoma on genetic insights <u>S.T. Lim</u> , Singapore, SG	
15:50 - 16:00	Discussion	

14:30 - 16:00	Multidisciplinary tumour board on salivary glands and unknown primary cancers Moderation: C. Simon, Lausanne, CH	Hall 404
14:30 - 14:35	Paranasal sinus: Case presentation	
14:35 - 15:00	Paranasal sinus <u>M.L.K. Chua</u> , Singapore, SG	
15:00 - 15:05	Salivary glands: Case presentation	
15:05 - 15:30	The role of chemotherapy for salivary gland cancer: Recent updates <u>B. Keam</u> , Seoul, KR	
15:30 - 15:35	Unknown primary cancers: Case presentation	
15:35 - 16:00	Unknown primary cancers <u>C. Simon</u> , Lausanne, CH	